HAVCR2 and neoplasm: Additionally, siRNA therapy successfully stimulated the antitumor function of T cells by downregulating the exhaustion markers PD-1 and T cell immunoglobulin mucin receptor 3 (TIM3) and stimulating the secretion of IFN-γ, dramatically inhibiting tumor growth and prolonging survival [99].